Skip to content
  • twitter
  • linkedin
  • onxeo
  • SUBSCRIBE TO OUR NEWS
  • EN
  • FR
  • CONTACT
Onxeo

Onxeo

Onxeo designs and develops novel oncology drugs targeting tumor DNA repair functions.

  • COMPANY
    • Profile
    • Executive Committee
    • Board of Directors
    • Join us
    • Contact us
  • SCIENCE
    • Scientific Advisory Committee
    • DNA Damage Response
    • platON™
    • Collaborations
  • PRODUCTS
    • DDR Pipeline
    • AsiDNA™
    • OX401
    • Other
  • INVESTORS
    • Regulated Information
      • Press Releases
      • Registration documents
      • Financial Information
      • Shares & Voting Rights
      • Share Repurchase/ Liquidity Agreement
      • Financial operations
      • Sponsor/ Advisor
    • Governance
      • Board Committees & Regulations
      • Directors’ Disclosures
      • Bylaws
    • Shareholder Resources
      • General Meetings
      • Financial Calendar
      • Stock Information
      • Shareholders’ Letters
    • Investor Relations
  • NEWS & EVENTS
    • Press Releases
    • Events & Presentations
    • Shareholder Letters
    • Media

Category: 2022

Publication of the 2021 Annual Financial Report

04/28/2022

Paris (France), April 28, 2022 – 6.00 pm CEST – Onxeo S.A. (Euronext Growth Paris: ALONX, Nasdaq First North Copenhagen: […]

Onxeo Appoints Dr. Shefali Agarwal as President and Chief Executive Officer

04/07/202204/06/2022

Agarwal is Currently Chairwoman of Onxeo’s Board, a Position Held Since June 2021 Company Outlines Development Strategy Plans Including Preparation […]

Onxeo Reports its Full-Year 2021 Financial Results and announces additional financing of €12 million

04/06/2022

Cash position of €17.9 million as of December 31, 2021 Additional financing of €12 million subscribed by historical shareholders Invus […]

Combined General Meeting (April 19, 2020 | 2:00 pm)

Extraordinary General Meeting (April 19, 2020 | 2:00 pm)

Onxeo to present new preclinical data highlighting AsiDNA™’s ability to fight tumor resistance and protect from anticancer treatment toxicity at AACR Annual Meeting 2022

03/31/202203/31/2022

AsiDNA™ proven to overcome resistance to tyrosine kinase inhibitors in lung cancer models AsiDNA™ proven to protect healthy cells when […]

AACR Annual Meeting 2022 (April 8 – 13, 2022)

AACR Annual Meeting 2022 (April 8 – 13, 2022)

Onxeo appoints Julien Miara as new interim CEO

01/03/202203/10/2022

Paris (France), January 3rd, 2022 – 6:00 pm CET – Onxeo S.A. (Euronext Growth Paris: ALONX, First North Copenhagen: ONXEO), (“Onxeo” or “the Company”), […]

Onxeo Announces its Financial Agenda for 2022

01/13/202203/10/2022

Paris (France), January 13, 2022 – 6 pm CET – Onxeo S.A. (Euronext Growth Paris: ALONX, First North Copenhagen: ONXEO), […]

Onxeo’s new preclinical data confirm the relevance of combining AsiDNA™ with PARP inhibitors in treating homologous recombination proficient tumors

03/09/202203/10/2022

These pioneering data were presented at ESMO Targeted Anticancer Therapies Congress 2022   Paris (France), March 9, 2022 – 7:00 […]

NEWS & EVENTS

  • Press Releases
  • Events & Presentations
  • Shareholder Letters
  • Media
Onxeo

> SITE MAP

> LEGAL NOTICES
> FOLLOW US

COMPANY

COMPANY


  • Profile
  • Executive Committee
  • Board of Directors
  • Join us
  • Contact us

SCIENCE

SCIENCE


  • DNA Damage Response
  • platON™
  • Collaborations

PRODUCTS

PRODUCTS


  • Pipeline
  • AsiDNA™
  • OX401
  • belinostat / Beleodaq®

INVESTORS

INVESTORS


  • Regulated Information
  • Governance
  • Shareholder Resources
  • Investor Relations

NEWS AND EVENTS

NEWS & RELEASES


  • Press Releases
  • Events & Presentations
  • NewsLetters
  • Media
SUBSCRIBE TO
OUR NEWS
CONTACT
US

ONXEO SA


49, avenue du Général Martial Valin
75015 PARIS – FRANCE
+33 (0) 1 45 58 76 00

© Copyright 2019 Onxeo
Photos : Onxeo - Design : 1sur1.net

Copyright © 2022 Onxeo All rights reserved. Theme: Flash by ThemeGrill. Powered by WordPress